Published on
July 28, 2025
- 21:27 GMT
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - Hagens ...
SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired Replimune ( …
Distribution channels:
Consumer Goods, Law
...
